Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Depreciation & Amortization (CF) (2018 - 2025)

X4 Pharmaceuticals' Depreciation & Amortization (CF) history spans 8 years, with the latest figure at $223000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 18.32% year-over-year to $223000.0; the TTM value through Dec 2025 reached $1.3 million, up 60.43%, while the annual FY2025 figure was $1.3 million, 60.43% up from the prior year.
  • Depreciation & Amortization (CF) reached $223000.0 in Q4 2025 per XFOR's latest filing, roughly flat from $223000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $476000.0 in Q1 2025 to a low of $62000.0 in Q4 2023.
  • Average Depreciation & Amortization (CF) over 5 years is $175200.0, with a median of $132000.0 recorded in 2021.
  • Peak YoY movement for Depreciation & Amortization (CF): plummeted 51.18% in 2024, then soared 667.74% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $132000.0 in 2021, then dropped by 6.06% to $124000.0 in 2022, then crashed by 50.0% to $62000.0 in 2023, then surged by 340.32% to $273000.0 in 2024, then fell by 18.32% to $223000.0 in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Depreciation & Amortization (CF) are $223000.0 (Q4 2025), $223000.0 (Q3 2025), and $355000.0 (Q2 2025).